20 Feb Stemina’s Human Induced Pluripotent Stem Cell Test Predicts Drug Cardiovascular Toxicity
Stemina Biomarker Discovery, Inc., today announced study results showing the high performance of the company’s Cardio quickPredict test in identifying cardiotoxic effects for a large number of well-characterized drugs.
These results suggest the drug screening test could provide drug developers with an early, highly accurate and more comprehensive evaluation of cardiovascular toxicity. The study, titled “A Targeted Metabolomics-Based Assay Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Identifies Structural and Functional Cardiotoxicity Potential,” was published in the journal Toxicological Sciences on February 10, 2020. The company is offering Cardio quickPredict as a compound safety screening service.